LSU Health Shreveport
Obstetrics and Gynecology residency · Shreveport, LA · Program website
This program's roster hasn't been collected yet, so there's no list of its own faculty and papers. Below is Louisiana State University Health Sciences Center Shreveport's research in obstetrics and gynecology, which the program shares with other departments and affiliated hospitals.
About Louisiana State University Health Sciences Center Shreveportinstitution-wide obstetrics and gynecology research
Obstetrics and Gynecology publications from Louisiana State University Health Sciences Center Shreveport and affiliated institutions, since 2022. Updated 2026-11-06; refreshed daily.
12
works per year
57th of 81 obstetrics and gynecology residency programs
+88.2%
2-year growth
5th of 80 obstetrics and gynecology residency programs
26.3%
in top 10% of field (works before 2025)
24th of 67 obstetrics and gynecology residency programs
39.5%
cited above world average
48th of 67 obstetrics and gynecology residency programs
Works per year · * 2026 so far
Obstetrics and Gynecology · 46Reproductive Medicine · 8
Obstetrics and Gynecology research topics at Louisiana State University Health Sciences Center Shreveport
Papers in the window; each links to the list on OpenAlex.
Most cited at Louisiana State University Health Sciences Center Shreveport since 2024
All obstetrics and gynecology papers there on OpenAlex
- ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancerToon Van Gorp et al. · Annals of Oncology · 2024 · PubMed · cited 103
- Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)Matthew A. Powell et al. · Gynecologic Oncology · 2024 · PubMed · cited 26
- ROCC/GOG-3043: a randomized controlled trial of robotic versus open surgery for early-stage cervical cancerMario M. Leitão et al. · International Journal of Gynecological Cancer · 2025 · PubMed · cited 17
- Incidence and Causes of Tubal Occlusion in Infertility: A Retrospective Cohort StudyDaniel Mayrhofer et al. · Journal of Clinical Medicine · 2024 · PubMed · cited 16
- The Protective Role of L-Cysteine in the Regulation of Blood–Testis Barrier Functions—A Brief ReviewJeffrey Justin Margret et al. · Genes · 2024 · PubMed · cited 15
- Overall survival among patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY TrialMatthew A. Powell et al. · Gynecologic Oncology · 2024 · cited 8
- L-Cysteine Upregulates Testosterone Biosynthesis and Blood–Testis Barrier Genes in Cultured Human Leydig Cells and THP-1 Monocytes and Increases Testosterone Secretion in Human Leydig CellsJeffrey Justin Margret et al. · Biomolecules · 2024 · PubMed · cited 8
- High Rates of Discordant Ureteral Perfusion During Open Ureteral Reconstruction With Indocyanine Green: Does Near-Infrared Fluorescence Imaging Change Management or Stricture Outcomes?Kevin J. Hebert et al. · Urology · 2024 · PubMed · cited 8
- 10O Efficacy according to PD-L1 status in the BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030) randomised phase III trial of first-line atezolizumab (atezo), chemotherapy (CT) and bevacizumab (bev) for metastatic, persistent or recurrent cervical cancer (R/M CC)Ugo De Giorgi et al. · ESMO Open · 2025 · cited 5
- 37MO Dostarlimab plus chemotherapy in primary advanced or recurrent endometrial cancer (pA/rEC) in the RUBY trial: Overall survival (OS) by MMR status and molecular subgroupsM.A. Powell et al. · ESMO Open · 2024 · cited 5